NewAmsterdam reports positive AD biomarker data from BROADWAY; p-tau217 reduced in ITT and ApoE4 carriers

NewAmsterdam Pharma Co N.V.

Statistically significant lower absolute change in p-tau217 over 12 months vs placebo in full ITT (p<0.002) and ApoE4 carriers (p=0.0215).
AD sub-study included 1,727 patients, 367 ApoE4 carriers; primary measure was p-tau217 change.
Company plans to present full results at AAIC conference in Toronto in July 2025.
Results build on prior genetic, preclinical, and Phase 2a data supporting CETP inhibition for AD prevention.
Obicetrapib is an oral CETP inhibitor primarily developed for LDL-C reduction; safety shown in large trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.